Ophthalmology Market Growing, But Eye Drug Earnings Potential Held by Few
Glaucoma and wet age-related macular degeneration sub-markets dominated the larger ophthalmology market with 36 percent and 32 percent shares, respectively, in 2011. By 2018, wet-AMD is expected to overtake glaucoma with 37 percent of the market, while glaucoma shrinks to 23 percent losing out to dry eye syndrome and diabetic macular edema.
Of he six largest ophthalmologic drug companies that control 70 percent of the market, Alcon, which was recently acquired by drug company Novartis, and Allergan have the biggest earnings potential in near-future drug development. Glaukos, the privately held company behind the iStent device for glaucoma treatment, is also promising, according to the report.
More Articles on Ophthalmology:Central Utah Clinic Opens New Eye Clinic, Adds Ophthalmologist
Common Coding Mistakes in Ambulatory Surgery Centers: 6 Specialties to Know (Part 2 of 3)
San Antonio Eye Center Adds Weekly Pediatric Clinic
© Copyright ASC COMMUNICATIONS 2015. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- Dr. Dolly Skeete joins Carolina Orthopedic & Sports Medicine: 5 key notes
- Big growth opportunities in the ASC space: Key thoughts from Nobilis Health Chairman Harry Fleming
- The changing principles of wound care
- Premiums go up, subsidized plan costs go down — 7 facts
- 5 key takeaways about the world's 1st Hepatitis D virus test